Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Inflammation and cancer : methods and protocols / edited by Serguei V. Kozlov
| Inflammation and cancer : methods and protocols / edited by Serguei V. Kozlov |
| Pubbl/distr/stampa | New York : Humana Press, 2009 |
| Descrizione fisica | 2 v. : ill. ; 27 cm |
| Disciplina | 616.994079 |
| Collana | Methods in molecular biology |
| Soggetto topico | Cancro -- Immunologia |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-990002237140203316 |
| New York : Humana Press, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Interaction of Immune and Cancer Cells [[electronic resource] /] / edited by Magdalena Klink, Izabela Szulc-Kielbik
| Interaction of Immune and Cancer Cells [[electronic resource] /] / edited by Magdalena Klink, Izabela Szulc-Kielbik |
| Edizione | [2nd ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (358 pages) |
| Disciplina | 616.994079 |
| Collana | Experientia Supplementum |
| Soggetto topico |
Tumors - Immunological aspects
Cancer - Treatment Oncology Tumour Immunology Cancer Therapy Cèl·lules T Anticossos monoclonals Oncologia Càncer Immunoteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-91311-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1: Cancer immunoediting - elimination, equilibrium and immune escape in solid tumors -- Chapter 2: Tumor – Stroma Interaction and Cancer. - Chapter 3: Tumor-infiltrating lymphocytes and their role in solid tumor progression -- Chapter 4: Tumor-associated macrophages – reasons to be cheerful, reasons to be fearful -- Chapter 5: Polymorphonuclear neutrophils and tumors: friend or foe? -- Chapter 6: Role of NK cells in tumor progression -- Chapter 7: The role of myeloid-derived suppressor cells in tumor growth and metastasis -- Chapter 8: Cancer stem cells – an ever hiding foe -- Chapter 9: Adoptive T-cell immunotherapy – Perfecting self-defenses -- Chapter 10: Monoclonal antibodies to CTLA-4 with focus on ipilimumab. |
| Record Nr. | UNINA-9910544846103321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
MHC Class-I Loss and Cancer Immune Escape [[electronic resource] /] / by Federico Garrido
| MHC Class-I Loss and Cancer Immune Escape [[electronic resource] /] / by Federico Garrido |
| Autore | Garrido Federico |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (109 pages) : illustrations |
| Disciplina | 616.994079 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Cancer research
Molecular biology Immunology Human genetics Cancer Research Molecular Medicine Human Genetics |
| ISBN | 3-030-17864-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Introduction -- Mhc/Hla Class I Loss In Cancer Cells -- Hla Class-I Expression And Cancer Immunotherapy -- Hla Class-Ii Expression In Human Tumors -- Index. |
| Record Nr. | UNINA-9910337952803321 |
Garrido Federico
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Regulation of Cancer Immune Checkpoints [[electronic resource] ] : Molecular and Cellular Mechanisms and Therapy / / edited by Jie Xu
| Regulation of Cancer Immune Checkpoints [[electronic resource] ] : Molecular and Cellular Mechanisms and Therapy / / edited by Jie Xu |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (X, 653 p. 105 illus., 57 illus. in color.) |
| Disciplina | 616.994079 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Cancer research
Immunology Molecular biology Cancer Research Molecular Medicine Càncer Immunitat cel·lular |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-3266-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks. |
| Record Nr. | UNINA-9910409705303321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Resistance to Immunotherapeutic Antibodies in Cancer [[electronic resource] ] : Strategies to Overcome Resistance / / edited by Benjamin Bonavida
| Resistance to Immunotherapeutic Antibodies in Cancer [[electronic resource] ] : Strategies to Overcome Resistance / / edited by Benjamin Bonavida |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | New York, NY : , : Springer New York : , : Imprint : Springer, , 2013 |
| Descrizione fisica | 1 online resource (210 p.) |
| Disciplina | 616.994079 |
| Collana | Resistance to Targeted Anti-Cancer Therapeutics |
| Soggetto topico |
Cancer research
Molecular biology Immunology Antibodies Cancer Research Molecular Medicine |
| ISBN | 1-4614-7654-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index. |
| Record Nr. | UNINA-9910739439503321 |
| New York, NY : , : Springer New York : , : Imprint : Springer, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy [[electronic resource] /] / edited by Pawel Kalinski
| Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy [[electronic resource] /] / edited by Pawel Kalinski |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (XIV, 264 p. 47 illus., 43 illus. in color.) |
| Disciplina | 616.994079 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Cancer research
Oncology Immunology Molecular biology Cancer Research Oncology Molecular Medicine |
| ISBN | 3-319-67577-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1. Interplay Between Tumor Cells, Stroma and Inflammatory Infiltrate in Regulating Tumor Micro-Environment -- Tumor Immuno-Environment in Cancer Progression and Therapy -- Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment -- Regulation of CTL Infiltration Within the Tumor Microenvironment -- The Role of Tumor Microenvironment in Cancer Immunotherapy -- Part 2. Mediators of Tumor Microenvironment -- Immunogenic and Non-Immunogenic Cell Death in the Tumor Microenvironment -- Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression -- Chemo-immunotherapy: Impact of Indoleamine 2,3-dioxygenase in Defining Immunogenic versus Tolerogenic Cell Death in the Tumor Microenvironment -- Targeting Myeloid-Derived Suppressor Cells in Cancer -- Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune Suppression -- Part 3. Emerging Targets and Technologies of Modulation of Tumor Microenvironment -- Tumor Microenvironment in Cancer Progression and Therapy -- The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma -- Oncolytic Virotherapy and the Tumor Microenvironment -- The Impact of Housing Temperature Induced Chronic Stress on Preclinical Mouse Tumor Models and Therapeutic Responses: An Important Role for the Nervous Role for the Nervous System -- (Immuno)therapeutic Targeting of Tumor-Associated Blood Vessels -- Adaptive Resistance to Cancer Immunotherapy -- Imaging the Tumor Microenvironment. |
| Record Nr. | UNINA-9910253958003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Tumor Immunoenvironment [[electronic resource] /] / edited by Michael R Shurin, Viktor Umansky, Anatoli Malyguine
| The Tumor Immunoenvironment [[electronic resource] /] / edited by Michael R Shurin, Viktor Umansky, Anatoli Malyguine |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2013 |
| Descrizione fisica | 1 online resource (745 p.) |
| Disciplina |
616.99
616.994079 |
| Soggetto topico |
Cancer research
Oncology Immunology Life sciences Medicine Cancer Research Oncology Life Sciences, general Biomedicine, general |
| ISBN | 94-007-6217-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Introduction -- Role of the immunological environment in cancer initiation, development and progression -- Part I Tumor Microenvironment and Immunoenvironment -- The metastatic microenvironment -- Tumor infiltration by immune cells: pathologic evaluation and a clinical significance -- Immunologic interpretation of cancer biology: impact on clinical outcome -- Part II Developmental Characteristics of the Tumor ImmunoEnvironment -- Development of antitumor cellular immunity -- The versatile world of inflammatory chemokines in cancer.-Inflammation, Tumor Progression, and Immune Suppression -- Pleiotropic and differential functions of IL-1a and IL-1b shape the tumor microenvironment and affect the outcome of malignancies -- Impact of obesity and aging on the tumor immunoenvironment -- Part III Tumor Escape from Immune Recognition -- MHC class I antigens and the tumor microenvironment -- Tumor-produced immune regulating factors -- Roles of signaling pathways in cancer cells and immune cells in generation of immunosuppressive tumor-associated microenvironments.- T cell malfunction in the tumor environment -- Signaling of tumor-induced immunosuppression of dendritic cells -- Tumor microenvironment may shape the function and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cells -- Part IV Immune Regulators in the Tumor ImmunoEnvironment -- The role of myeloid-derived suppressor cells in cancer -- Macrophage differentiation and activation states in the tumor microenvironment -- Dendritic cells and cancer: development, dysfunction and therapeutic targets -- The role of tumor-associated neutrophils in cancer -- Mast cell modulation of the tumor microenvironment -- Regulatory T cells in patients with cancer -- Tumor-evoked regulatory B cells as important mediators of cancer escape -- Part V Tumor Escape and Cancer Immunotherapy -- Cancer immunotherapy: Overview in brief -- Programming of MDSC: New opportunities for targeted therapy -- Therapeutic targeting regulatory T cells in tumor.-ChemoImmunoModulation: Focus on myeloid regulatory cells -- Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing -- Prophylactic Cancer Vaccines -- Part VI Analyzing Immune Responses in Cancer -- Approaches to Immunologic Monitoring of Clinical Trials -- Evaluation of the tumor immunoenvironment in clinical trials -- Analysis of Myeloid-derived Suppressor Cells in Patients with Cancer -- When results of T cell immune monitoring match or do not match clinical outcomes of tumor vaccine trials - what more could and should we measure? |
| Record Nr. | UNINA-9910437855403321 |
| Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tumor Microenvironment [[electronic resource] /] / edited by Peter P. Lee, Francesco M. Marincola
| Tumor Microenvironment [[electronic resource] /] / edited by Peter P. Lee, Francesco M. Marincola |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (XXIV, 326 p. 61 illus., 56 illus. in color.) |
| Disciplina | 616.994079 |
| Collana | Cancer Treatment and Research |
| Soggetto topico |
Oncology
Immunology Oncology |
| ISBN | 3-030-38862-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Part I: Imaging of tumor microenvironment, In vivo Imaging -- New technologies to image tumors -- Part II: Immune landscapes and their biology, Systemic correlates of the tumor microenvironment -- Adaptive immunity and the tumor microenvironment -- The biology of immune active cancers and their regulatory mechanisms -- The biology of immune excluded cancers -- Immunoscore -- Part III: The tumor microenvironment and therapy, The Immune Landscape in Women Cancers -- Translational biomarkers, combination therapies and their relationship with immune landscapes -- Effects of radiation on the tumor microenvironment -- Challenges of CAR T cell therapy for solid tumors. |
| Record Nr. | UNINA-9910383832303321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tumor-associated antigens [[electronic resource] ] : identification, characterization, and clinical applications / / edited by Olivier Gires and Barbara Seliger
| Tumor-associated antigens [[electronic resource] ] : identification, characterization, and clinical applications / / edited by Olivier Gires and Barbara Seliger |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2009 |
| Descrizione fisica | 1 online resource (386 p.) |
| Disciplina | 616.994079 |
| Altri autori (Persone) |
GiresOlivier
SeligerBarbara |
| Soggetto topico |
Tumor antigens
Tumors - Immunological aspects |
| ISBN |
1-282-02189-3
9786612021893 3-527-62597-6 3-527-62598-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Tumor-Associated Antigens : Identification, Characterization, and Clinical Applications; Contents; List of Contributors; Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs; 1 T Cell Antigens in Cancer; 1.1 Introduction; 1.2 Generation of T-cell Epitopes; 1.2.1 Subclasses of Tumor-associated T-cell Antigens; 1.2.1.1 Unique Tumor Antigens; 1.2.1.2 Cancer Testis Antigens; 1.2.1.3 Differentiation Antigens; 1.2.1.4 Overexpressed Antigens; 1.3 Identification of T-cell Antigens and their Epitopes; 1.3.1 T-cell Antigens for Cancer Immunotherapy - How are Candidates Selected?
1.4 ConclusionsReferences; 2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines; 2.1 Introduction; 2.2 Tumor Antigen Classes; 2.2.1 Oncofetal Antigens; 2.2.2 Oncogenes as Tumor Antigens; 2.2.3 Overexpressed Normal Molecules as Tumor Antigens; 2.2.4 Cancer-Testis (CT) Antigens; 2.2.5 Minor Histocompatibility Antigens (mHAgs) as Tumor Antigens; 2.2.6 Human Melanoma Antigens; 2.2.7 Human Glioma Antigens and Immunosurveillance in the CNS; 2.2.8 Heat Shock Proteins, Efficient Carriers of Tumor Antigens 2.2.9 Dendritic Cells, Efficient Cross-presenters of Tumor Antigens2.2.10 Spontaneous and Vaccine-induced Immunity and the Tumor Microenvironment; 2.3 Summary; References; Part Two Methods to Detect TAAs; 3 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part I: SEREX; 3.1 Introduction; 3.2 The SEREX Approach; 3.2.1 Identification of Human Tumor Antigens by SEREX; 3.2.2 Specificity of Human Tumor Antigens; 3.2.2.1 Shared Tumor Antigens; 3.2.2.2 Differentiation Antigens; 3.2.2.3 Antigens Encoded by Mutated Genes; 3.2.2.4 Viral Genes 3.2.2.5 Overexpressed Genes3.2.2.6 Amplified Genes; 3.2.2.7 Splice Variants of Known Genes; 3.2.2.8 Cancer-related Autoantigens; 3.2.2.9 Non-cancer-related Autoantigens; 3.2.2.10 Products of Underexpressed Genes; 3.2.3 Significance of Antibodies against SEREX Antigens; 3.2.4 Reverse T Cell Immunology; 3.2.5 Functional Significance of Human Tumor Antigens; 3.2.6 The Human Cancer Immunome; 3.2.7 Perspectives for Vaccine Development; 3.3 Conclusions; References; 4 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA; 4.1 Introduction 4.1.1 A Humoral Response against Self-antigens: The Notion of Tumor-associated Antigens4.2 Implementation of Serum Antibodies: Serological Screening Technologies; 4.2.1 PROTEOMEX, alias SERPA and SPEARS; 4.2.1.1 PROTEOMEX Technology and its 'Pros' and 'Cons'; 4.2.1.2 Candidate Biomarkers Identified by PROTEOMEX; 4.2.1.3 Implementation of Candidate Biomarkers in the Clinic; 4.2.2 AMIDA; 4.2.2.1 Autologous AMIDA; 4.2.2.2 Allo-AMIDA; 4.2.3 Advantages and Disadvantages of AMIDA; 4.3 AMIDA Antigens and Clinical Application; 4.3.1 Diagnostic TAAs Detected with AMIDA Screening 4.3.2 Therapeutic Markers |
| Record Nr. | UNINA-9910146099803321 |
| Weinheim, : Wiley-VCH, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Tumor-associated antigens [[electronic resource] ] : identification, characterization, and clinical applications / / edited by Olivier Gires and Barbara Seliger
| Tumor-associated antigens [[electronic resource] ] : identification, characterization, and clinical applications / / edited by Olivier Gires and Barbara Seliger |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2009 |
| Descrizione fisica | 1 online resource (386 p.) |
| Disciplina | 616.994079 |
| Altri autori (Persone) |
GiresOlivier
SeligerBarbara |
| Soggetto topico |
Tumor antigens
Tumors - Immunological aspects |
| ISBN |
1-282-02189-3
9786612021893 3-527-62597-6 3-527-62598-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Tumor-Associated Antigens : Identification, Characterization, and Clinical Applications; Contents; List of Contributors; Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs; 1 T Cell Antigens in Cancer; 1.1 Introduction; 1.2 Generation of T-cell Epitopes; 1.2.1 Subclasses of Tumor-associated T-cell Antigens; 1.2.1.1 Unique Tumor Antigens; 1.2.1.2 Cancer Testis Antigens; 1.2.1.3 Differentiation Antigens; 1.2.1.4 Overexpressed Antigens; 1.3 Identification of T-cell Antigens and their Epitopes; 1.3.1 T-cell Antigens for Cancer Immunotherapy - How are Candidates Selected?
1.4 ConclusionsReferences; 2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines; 2.1 Introduction; 2.2 Tumor Antigen Classes; 2.2.1 Oncofetal Antigens; 2.2.2 Oncogenes as Tumor Antigens; 2.2.3 Overexpressed Normal Molecules as Tumor Antigens; 2.2.4 Cancer-Testis (CT) Antigens; 2.2.5 Minor Histocompatibility Antigens (mHAgs) as Tumor Antigens; 2.2.6 Human Melanoma Antigens; 2.2.7 Human Glioma Antigens and Immunosurveillance in the CNS; 2.2.8 Heat Shock Proteins, Efficient Carriers of Tumor Antigens 2.2.9 Dendritic Cells, Efficient Cross-presenters of Tumor Antigens2.2.10 Spontaneous and Vaccine-induced Immunity and the Tumor Microenvironment; 2.3 Summary; References; Part Two Methods to Detect TAAs; 3 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part I: SEREX; 3.1 Introduction; 3.2 The SEREX Approach; 3.2.1 Identification of Human Tumor Antigens by SEREX; 3.2.2 Specificity of Human Tumor Antigens; 3.2.2.1 Shared Tumor Antigens; 3.2.2.2 Differentiation Antigens; 3.2.2.3 Antigens Encoded by Mutated Genes; 3.2.2.4 Viral Genes 3.2.2.5 Overexpressed Genes3.2.2.6 Amplified Genes; 3.2.2.7 Splice Variants of Known Genes; 3.2.2.8 Cancer-related Autoantigens; 3.2.2.9 Non-cancer-related Autoantigens; 3.2.2.10 Products of Underexpressed Genes; 3.2.3 Significance of Antibodies against SEREX Antigens; 3.2.4 Reverse T Cell Immunology; 3.2.5 Functional Significance of Human Tumor Antigens; 3.2.6 The Human Cancer Immunome; 3.2.7 Perspectives for Vaccine Development; 3.3 Conclusions; References; 4 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA; 4.1 Introduction 4.1.1 A Humoral Response against Self-antigens: The Notion of Tumor-associated Antigens4.2 Implementation of Serum Antibodies: Serological Screening Technologies; 4.2.1 PROTEOMEX, alias SERPA and SPEARS; 4.2.1.1 PROTEOMEX Technology and its 'Pros' and 'Cons'; 4.2.1.2 Candidate Biomarkers Identified by PROTEOMEX; 4.2.1.3 Implementation of Candidate Biomarkers in the Clinic; 4.2.2 AMIDA; 4.2.2.1 Autologous AMIDA; 4.2.2.2 Allo-AMIDA; 4.2.3 Advantages and Disadvantages of AMIDA; 4.3 AMIDA Antigens and Clinical Application; 4.3.1 Diagnostic TAAs Detected with AMIDA Screening 4.3.2 Therapeutic Markers |
| Record Nr. | UNINA-9910829813803321 |
| Weinheim, : Wiley-VCH, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
